Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAL vs CALCIUM DISODIUM VERSENATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.
Arsenic poisoning,Mercury poisoning,Lead poisoning (adjunct to edetate calcium disodium),Acute gold poisoning,Wilson's disease (investigational)
Treatment of lead poisoning (including symptomatic and asymptomatic patients with blood lead levels ≥45 μg/d L in children and ≥70 μg/d L in adults),Off-label: treatment of other heavy metal toxicities (e.g., cadmium, chromium, manganese, nickel)
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Terminal elimination half-life: 20-30 minutes for unchelated drug; lead-chelate complex half-life: 1-2 hours. Clinical context: Short half-life necessitates continuous or repeated dosing for sustained chelation.
Primarily hepatic; undergoes oxidation and conjugation; metabolites excreted renally.
Not metabolized; excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Renal: >95% as chelated lead complex; biliary/fecal: negligible (<5%)
BAL is extensively bound to plasma proteins, primarily albumin, with protein binding >90%.
<5% bound to plasma proteins (albumin)
Volume of distribution is approximately 3.5 L/kg, indicating extensive distribution into tissues, including brain and intracellular spaces.
0.2-0.3 L/kg; primarily distributes to extracellular fluid, minimal intracellular penetration
BAL is not administered orally due to poor absorption and gastrointestinal irritation. Given intravenously, bioavailability is 100%. Intramuscular bioavailability is similar but with slower absorption.
IV: 100%; IM: approximately 80-90% (due to local chelation and partial excretion)
GFR 10-50 m L/min: reduce frequency to every 6-8 hours; GFR <10 m L/min: reduce frequency to every 8-12 hours.
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of usual dose; GFR < 10 m L/min: administer 25% of usual dose or consider alternative therapy.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% and monitor for hepatotoxicity.
No specific guidelines available; use with caution and monitor liver function in severe hepatic impairment (Child-Pugh C).
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days; maximum 100 mg per dose.
25 mg/kg/dose intramuscularly or intravenously every 12 hours for 3-5 days; maximum 1 g/dose.
Start at 3 mg/kg IM every 6 hours; adjust based on renal function, monitor for hypotension and pain at injection site.
Consider renal function; elderly patients often require dose reduction based on creatinine clearance; start at lower end of dosing range and monitor for adverse effects.
None.
This drug is not indicated for the treatment of iron deficiency anemia or hemochromatosis. Do not use in patients with severe renal impairment. Prolonged or excessive use may lead to toxicities including renal failure, convulsions, and cardiac arrhythmias.
Monitor renal function and serum electrolytes during therapy.,Can cause hypertension, tachycardia, and myocardial ischemia; use cautiously in cardiovascular disease.,May induce hemolytic anemia in patients with G6PD deficiency.,Injection site reactions and sterile abscesses may occur.,Iron deficiency is a known adverse effect due to iron chelation.
Renal toxicity: monitor renal function and urine output; avoid excessive doses. Neurotoxicity: can cause tremors, seizures, and encephalopathy, especially with high doses or rapid infusion. Hydration: maintain adequate hydration to promote urinary excretion. Rebound metal mobilization: may transiently increase tissue metal levels. Hypocalcemia: due to calcium displacement; monitor serum calcium. Cardiac effects: risk of arrhythmias, especially with rapid IV administration.
Hypersensitivity to BAL or any component.,Hepatic insufficiency (unless benefit outweighs risk).,Iron poisoning (forms toxic complex).,Concurrent use with cadmium or selenium (increased toxicity).
Absolute: anuria or severe renal failure (creatinine clearance <20 m L/min). Relative: hypersensitivity to edetate salts, pre-existing renal disease, concurrent use with other nephrotoxic drugs.
Avoid alcohol and caffeine. Maintain adequate hydration. No specific food restrictions, but ensure iron-rich foods are avoided if concurrent iron poisoning suspected (though BAL not indicated for iron).
Avoid excessive intake of calcium and vitamin D supplements during therapy (may reduce chelation efficacy). Maintain adequate hydration with water. No specific food restrictions, but a balanced diet is recommended to prevent deficiencies of essential minerals (zinc, copper) that may be chelated.
Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.
Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fetal zinc/corper deficiency if prolonged use. Avoid unless maternal benefit outweighs risk.
BAL (dimercaprol) is excreted into breast milk; M/P ratio unknown. Limited data; exercise caution and consider temporary cessation of breastfeeding during therapy.
Excreted into breast milk in low amounts; M/P ratio unknown. Caution due to potential for infant mineral chelation. Use only if clearly needed.
No specific dose adjustments recommended in pregnancy; monitor for increased volume of distribution and potential need for higher doses if toxicity persists.
No specific dose adjustment required; however, monitor for hypocalcemia and mineral depletion. Increased risk of renal toxicity in pregnancy; ensure adequate hydration.
BAL (dimercaprol) is used as a chelating agent for heavy metal poisoning, particularly arsenic, lead, and mercury. Administer deep IM only; avoid IV due to risk of hemolysis. Monitor blood pressure closely as hypertension can occur. Contraindicated in peanut allergy due to peanut oil vehicle. Administer with alkaline urine to protect kidneys.
Administer deep IM or slow IV infusion (over 2-4 hours) to avoid thrombophlebitis. Monitor urine output and renal function; nephrotoxicity is dose-dependent. Discontinue if oliguria or rising creatinine occurs. For lead encephalopathy, give concurrently with BAL (dimercaprol) to redistribute lead from CNS to blood. Use with caution in patients with pre-existing renal disease, hepatitis, or history of allergic reactions. EDTA can chelate essential metals (zinc, copper) leading to deficiencies during prolonged therapy.
This medication is given as an injection into a muscle.,You may experience a metallic taste, headache, or nausea.,Report any signs of allergic reaction such as rash or difficulty breathing.,Avoid alcohol while on this medication.,Do not drive or operate heavy machinery until you know how this drug affects you.
Report any signs of allergic reaction (rash, itching, difficulty breathing) or injection site pain/swelling immediately.,Drink plenty of fluids (unless instructed otherwise) to help flush out lead through urine.,Avoid taking any other medications, supplements, or over-the-counter products without consulting your doctor, as they may affect treatment.,Do not miss scheduled blood and urine tests; they are essential to monitor lead levels and kidney function.,Severe lead poisoning may cause fatigue, headache, abdominal pain; report these symptoms if they worsen.
"Pregabalin, a gabapentinoid, enhances the inhibitory effects of GABA by binding to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Dapiprazole, an α1-adrenoceptor antagonist used for miosis, can have its therapeutic efficacy increased when combined with pregabalin due to additive central nervous system depression. This interaction may result in enhanced sedation, dizziness, and psychomotor impairment, potentially increasing the risk of falls and cognitive dysfunction."
"Pregabalin and pravastatin may exhibit an additive risk of musculoskeletal adverse effects, particularly myopathy and rhabdomyolysis, due to their overlapping effects on muscle cells. Pregabalin can cause dose-related muscle damage, while pravastatin inhibits HMG-CoA reductase, leading to reduced skeletal muscle integrity. This combination may potentiate serum creatine kinase elevations and increase the likelihood of clinical myopathy, especially in patients with predisposing factors such as renal impairment or concomitant use of other myotoxic agents."
"Pregabalin may cause fluid retention and peripheral edema, which can precipitate or exacerbate heart failure, especially in patients with pre-existing cardiac risk factors. Rosiglitazone, a thiazolidinedione, also promotes fluid retention and increases plasma volume via PPAR-γ-mediated renal effects. When combined, the additive fluid-retaining properties of both drugs can synergistically elevate the risk of new-onset or worsening heart failure, particularly in patients with reduced left ventricular function or NYHA Class III/IV status."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAL vs CALCIUM DISODIUM VERSENATE, answered by our medical review team.
BAL is a Chelating Agent that works by Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.. CALCIUM DISODIUM VERSENATE is a Chelating Agent that works by Calcium disodium edetate chelates heavy metals (e.g., lead, cadmium) forming stable, water-soluble complexes that are excreted renally, reducing metal burden and toxicity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAL and CALCIUM DISODIUM VERSENATE depend on the specific clinical indication. These are both Chelating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAL is: 3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.. The standard adult dose of CALCIUM DISODIUM VERSENATE is: 1-2 g intramuscularly or intravenously every 12 hours for 3-5 days, followed by 2-5 days off, repeating as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAL and CALCIUM DISODIUM VERSENATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAL is classified as Category C. Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.. CALCIUM DISODIUM VERSENATE is classified as Category C. Limited human data. Animal studies show fetal toxicity at high doses. First trimester: theoretical risk of chelation of essential minerals. Second and third trimesters: risk of fet. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.